Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Michael Amoroso Biography and Net Worth

CEO of Abeona Therapeutics

Prior to joining Abeona, Mr. Amoroso held various senior level commercial positions at leading biopharmaceutical companies, including Kite, Eisai Inc., Celgene Corporation (now a subsidiary of Bristol-Myers Squibb Company), and Sanofi. At Kite, he was responsible for the company’s worldwide commercial organization leading the commercialization efforts for the autologous CAR T-cell therapy, YESCARTA®, and the future cell therapy pipeline. Before Kite, Mr. Amoroso was Senior Vice President, Americas for Eisai’s Commercial Oncology Business Group, where he was accountable for teams charged with creating and driving commercial strategy and implementation for the company’s approved products and earlier-stage assets. Previously, Mr. Amoroso worked at Celgene for six years in several commercial roles before serving as the organization’s Commercial Lead for CAR T-cell therapy programs. In this capacity, he helped Celgene develop an organizational model to commercialize cell therapies including specialized manufacturing and customer services for patients with lymphoma and myeloma. Before joining Celgene, Mr. Amoroso held various marketing and sales leadership positions over his 10-plus year tenure at Sanofi. Mr. Amoroso earned his M.B.A. in Management from the Stern School of Business, New York University, and his B.A. in Biological Sciences, summa cum laude, from Rider University

What is Michael Amoroso's net worth?: The estimated net worth of Michael Amoroso is at least $89,939.17 as of January 22nd, 2024. Mr. Amoroso owns 11,881 shares of Abeona Therapeutics stock worth more than $89,939 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Amoroso may own. Learn More about Michael Amoroso's net worth.
How do I contact Michael Amoroso?: The corporate mailing address for Mr. Amoroso and other Abeona Therapeutics executives is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. Abeona Therapeutics can also be reached via phone at 214-665-9495 and via email at [email protected]. Learn More on Michael Amoroso's contact information.
Has Michael Amoroso been buying or selling shares of Abeona Therapeutics?: Michael Amoroso has not been actively trading shares of Abeona Therapeutics over the course of the past ninety days. Most recently, Michael Amoroso sold 327 shares of the business's stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $3.90, for a transaction totalling $1,275.30. Following the completion of the sale, the director now directly owns 114,465 shares of the company's stock, valued at $446,413.50. Learn More on Michael Amoroso's trading history.
Who are Abeona Therapeutics' active insiders?: Abeona Therapeutics' insider roster includes Michael Amoroso (CEO), Edward Carr (CAO), Brendan O'Malley (SVP), and Todd Wider (Director). Learn More on Abeona Therapeutics' active insiders.
Are insiders buying or selling shares of Abeona Therapeutics?: During the last twelve months, Abeona Therapeutics insiders bought shares 2 times. They purchased a total of 23,000 shares worth more than $92,800.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 14,079 shares worth more than $63,728.94. The most recent insider tranaction occured on January, 17th when Director Mark Alvino sold 7,084 shares worth more than $36,199.24. Insiders at Abeona Therapeutics own 5.3% of the company. Learn More about insider trades at Abeona Therapeutics.
Information on this page was last updated on 1/17/2024.

Michael Amoroso Insider Trading History at Abeona Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/20/2023	Sell	327	$3.90	$1,275.30	114,465
6/20/2023	Sell	338	$4.45	$1,504.10	114,792
3/20/2023	Sell	268	$2.33	$624.44	56,441
3/3/2023	Sell	1,002	$2.38	$2,384.76	56,709
9/30/2021	Sell	45,409	$1.09	$49,495.81
3/31/2021	Sell	45,409	$1.87	$84,914.83	650,046

Michael Amoroso Buying and Selling Activity at Abeona Therapeutics

Abeona Therapeutics Company Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Today's Range

Now: $7.57

$7.20

$7.69

50 Day Range

MA: $7.47

$6.15

$8.68

2 Week Range

Now: $7.57

$2.83

$9.01

Volume

386,264 shs

Average Volume

325,152 shs

Market Capitalization

$207.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49